{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:50:02Z","timestamp":1793620202453,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Pennsylvania Medical Device Accelerator Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of opioid-related overdose deaths has been rising for 30\u00a0years and has been further exacerbated amidst the COVID-19 pandemic. Naloxone can reverse opioid overdose, lower death rates, and enable a transition to medication for opioid use disorder. Though current formulations for community use of naloxone have been shown to be safe and effective public health interventions, they rely on bystander presence. We sought to understand the preferences and minimum necessary conditions for wearing a device capable of sensing and reversing opioid overdose among people who regularly use opioids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a combined cross-sectional survey and semi-structured interview at a respite center, shelter, and syringe exchange drop-in program in Philadelphia, Pennsylvania, USA, during the COVID-19 pandemic in August and September 2020. The primary aim was to explore the proportion of participants who would use a wearable device to detect and reverse overdose. Preferences regarding designs and functionalities were collected via a questionnaire with items having Likert-based response options and a semi-structured interview intended to elicit feedback on prototype designs. Independent variables included demographics, opioid use habits, and previous experience with overdose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 97 adults with an opioid use history of at least 3\u00a0months were interviewed. A majority of survey participants (76%) reported a willingness to use a device capable of detecting an overdose and automatically administering a reversal agent upon initial survey. When reflecting on the prototype, most respondents (75.5%) reported that they would wear the device always or most of the time. Respondents indicated discreetness and comfort as important factors that increased their chance of uptake. Respondents suggested that people experiencing homelessness and those with low tolerance for opioids would be in greatest need of the device.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The majority of people sampled with a history of opioid use in an urban setting were interested in having access to a device capable of detecting and reversing an opioid overdose. Participants emphasized privacy and comfort as the most important factors influencing their willingness to use such a device.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Trial registration<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>NCT04530591.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-021-00522-3","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T07:03:02Z","timestamp":1627023782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Willingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in Philadelphia"],"prefix":"10.1186","volume":"18","author":[{"given":"Katie","family":"Kanter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feyisope","family":"Eweje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Landy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gasior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haideliza","family":"Soto-Calderon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Cronholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Cocchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lankenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8437-0161","authenticated-orcid":false,"given":"Jacob","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"issue":"6408","key":"522_CR1","doi-asserted-by":"publisher","first-page":"eaau1184","DOI":"10.1126\/science.aau1184","volume":"361","author":"H Jalal","year":"2018","unstructured":"Jalal H, et al. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018;361(6408):eaau1184.","journal-title":"Science"},{"key":"522_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","volume":"67","author":"L Scholl","year":"2018","unstructured":"Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths\u2014United States, 2013\u20132017. MMWR Morb Mortal Wkly Rep. 2018;67:1419\u201327.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"522_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41398-019-0625-0","volume":"9","author":"Y Han","year":"2019","unstructured":"Han Y, et al. The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. Transl Psychiatry. 2019;9:282.","journal-title":"Transl Psychiatry"},{"key":"522_CR4","doi-asserted-by":"publisher","unstructured":"Anderson RN. National Vital Statistics Reports. Encycl Hum Dev. 2013:68(3). https:\/\/doi.org\/10.4135\/9781412952484.n432.","DOI":"10.4135\/9781412952484.n432"},{"key":"522_CR5","unstructured":"NCHS, National Vital Statistics System. Percent of drug overdose deaths by quarter and demographic characteristics: United States 2018-Q1 through 2020-Q1. https:\/\/www.cdc.gov\/nchs\/data\/health_policy\/Provisional-Drug-Overdose-Deaths-by-Quarter-Demographic-Characteristics-Q1-2020.pdf."},{"key":"522_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.drugalcdep.2016.02.024","volume":"162","author":"A Caudarella","year":"2016","unstructured":"Caudarella A, et al. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016;162:51\u20135.","journal-title":"Drug Alcohol Depend"},{"key":"522_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2019.07.030","volume":"73","author":"S Colledge","year":"2019","unstructured":"Colledge S, et al. The prevalence of non-fatal overdose among people who inject drugs: a multi-stage systematic review and meta-analysis. Int J Drug Policy. 2019;73:172\u201384.","journal-title":"Int J Drug Policy"},{"key":"522_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40122-018-0096-7","volume":"7","author":"EA Shipton","year":"2018","unstructured":"Shipton EA, Shipton EE, Shipton AJ. A review of the opioid epidemic: what do we do about it? Pain Ther. 2018;7:23\u201336.","journal-title":"Pain Ther"},{"key":"522_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/15563650.2018.1529319","volume":"57","author":"NC Stam","year":"2019","unstructured":"Stam NC, Gerostamoulos D, Smith K, Pilgrim JL, Drummer OH. Challenges with take-home naloxone in reducing heroin mortality: a review of fatal heroin overdose cases in Victoria, Australia. Clin Toxicol Phila Pa. 2019;57:325\u201330.","journal-title":"Clin Toxicol Phila Pa"},{"key":"522_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugpo.2017.12.020","volume":"55","author":"RP Ogeil","year":"2018","unstructured":"Ogeil RP, et al. Pharmaceutical opioid overdose deaths and the presence of witnesses. Int J Drug Policy. 2018;55:8\u201313.","journal-title":"Int J Drug Policy"},{"key":"522_CR11","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.2105\/AJPH.2013.301709","volume":"104","author":"KM Keyes","year":"2013","unstructured":"Keyes KM, Cerd\u00e1 M, Brady JE, Havens JR, Galea S. Understanding the rural\u2013urban differences in nonmedical prescription opioid use and abuse in the United States. Am J Public Health. 2013;104:e52\u20139.","journal-title":"Am J Public Health"},{"key":"522_CR12","doi-asserted-by":"publisher","first-page":"155798831985911","DOI":"10.1177\/1557988319859113","volume":"13","author":"G Bardwell","year":"2019","unstructured":"Bardwell G, Kerr T, McNeil R. The opioid overdose epidemic and the urgent need for effective public health interventions that address men who use drugs alone. Am J Mens Health. 2019;13:1557988319859113.","journal-title":"Am J Mens Health"},{"key":"522_CR13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/add.14508","volume":"114","author":"JM Wojcicki","year":"2019","unstructured":"Wojcicki JM. Dying alone: the sad irrelevance of naloxone in the context of solitary opiate use. Addiction. 2019;114:574\u20135.","journal-title":"Addiction"},{"key":"522_CR14","unstructured":"\u201cBe Safe App.\u201d BRAVE, Brave Technology Group. http:\/\/www.brave.coop\/besafe."},{"key":"522_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/jamiaopen\/ooz068","volume":"3","author":"G Marcu","year":"2020","unstructured":"Marcu G, Aizen R, Roth AM, Lankenau S, Schwartz DG. Acceptability of smartphone applications for facilitating layperson naloxone administration during opioid overdoses. JAMIA Open. 2020;3:44\u201352.","journal-title":"JAMIA Open"},{"key":"522_CR16","doi-asserted-by":"publisher","first-page":"100474","DOI":"10.1016\/j.eclinm.2020.100474","volume":"25","author":"DG Schwartz","year":"2020","unstructured":"Schwartz DG, et al. Layperson reversal of opioid overdose supported by smartphone alert: a prospective observational cohort study. EClinicalMedicine. 2020;25:100474.","journal-title":"EClinicalMedicine"},{"key":"522_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12905-021-01196-6","volume":"21","author":"G Bardwell","year":"2021","unstructured":"Bardwell G, Fleming T, McNeil R, Boyd J. Women\u2019s multiple uses of an overdose prevention technology to mitigate risks and harms within a supportive housing environment: a qualitative study. BMC Womens Health. 2021;21:51.","journal-title":"BMC Womens Health"},{"key":"522_CR18","unstructured":"Shuren J, Jarow J. Inspiring medical device innovation to combat the opioid crisis. FDA Voices. 2018. https:\/\/www.fda.gov\/news-events\/fda-voices\/inspiring-medical-device-innovation-combat-opioid-crisis."},{"key":"522_CR19","doi-asserted-by":"publisher","unstructured":"Mahmud MS, Fang H, Wang H, Carreiro S, Boyer E. Automatic detection of opioid intake using wearable biosensor. In: 2018 international conference on computing, networking and communications (ICNC). IEEE; 2018. pp. 784\u2013788. https:\/\/doi.org\/10.1109\/ICCNC.2018.8390334.","DOI":"10.1109\/ICCNC.2018.8390334"},{"key":"522_CR20","doi-asserted-by":"publisher","unstructured":"Wang J, Fang H, Carreiro S, Wang H, Boyer E. A new mining method to detect real time substance use events from wearable biosensor data stream. In: 2017 international conference on computing, networking and communications (ICNC). IEEE; 2017. pp. 465\u2013470. https:\/\/doi.org\/10.1109\/ICCNC.2017.7876173.","DOI":"10.1109\/ICCNC.2017.7876173"},{"key":"522_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s13181-014-0439-7","volume":"11","author":"S Carreiro","year":"2015","unstructured":"Carreiro S, et al. Real-time mobile detection of drug use with wearable biosensors: a pilot study. J Med Toxicol. 2015;11:73\u20139.","journal-title":"J Med Toxicol"},{"key":"522_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s13181-016-0557-5","volume":"12","author":"S Carreiro","year":"2016","unstructured":"Carreiro S, et al. Wearable biosensors to detect physiologic change during opioid use. J Med Toxicol. 2016;12:255\u201362.","journal-title":"J Med Toxicol"},{"key":"522_CR23","doi-asserted-by":"publisher","first-page":"eaau8914","DOI":"10.1126\/scitranslmed.aau8914","volume":"11","author":"R Nandakumar","year":"2019","unstructured":"Nandakumar R, Gollakota S, Sunshine JE. Opioid overdose detection using smartphones. Sci Transl Med. 2019;11:eaau8914.","journal-title":"Sci Transl Med"},{"key":"522_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2019.05.041","volume":"306","author":"B Dhowan","year":"2019","unstructured":"Dhowan B, et al. Simple minimally-invasive automatic antidote delivery device (A2D2) towards closed-loop reversal of opioid overdose. J Control Release Off J Control Release Soc. 2019;306:130\u20137.","journal-title":"J Control Release Off J Control Release Soc"},{"key":"522_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13722-019-0153-5","volume":"14","author":"K Ahamad","year":"2019","unstructured":"Ahamad K, et al. Factors associated with willingness to wear an electronic overdose detection device. Addict Sci Clin Pract. 2019;14:23.","journal-title":"Addict Sci Clin Pract"},{"key":"522_CR26","first-page":"1","volume":"5","author":"Philadelphia Department of Public Health","year":"2020","unstructured":"Philadelphia Department of Public Health. The impact of COVID-19 on unintentional drug overdoses in Philadelphia. Chart. 2020;5:1\u20136.","journal-title":"Chart"},{"key":"522_CR27","unstructured":"Whelan A. How Philly plans to combat the nation\u2019s worst big-city opioid crisis in 2020. https:\/\/www.inquirer.com\/health\/opioid-addiction\/whats-next-2020-opioid-crisis-overdoses-philadelphia-kensington-20200121.html."},{"key":"522_CR28","unstructured":"Oetting ER, Edwards RW, Beauvais F. American Drug and Alcohol Survey (ADAS). 1984. https:\/\/adai.uw.edu\/instruments\/pdf\/ADAS_287.pdf."},{"key":"522_CR29","unstructured":"New York State Department of Health. How to use injection naloxone for opioid overdose. 3. https:\/\/www.health.ny.gov\/publications\/0161.pdf."},{"key":"522_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drugalcdep.2016.12.013","volume":"173","author":"D Madah-Amiri","year":"2017","unstructured":"Madah-Amiri D, Clausen T, Lobmaier P. Rapid widespread distribution of intranasal naloxone for overdose prevention. Drug Alcohol Depend. 2017;173:17\u201323.","journal-title":"Drug Alcohol Depend"},{"issue":"33","key":"522_CR31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.15585\/mmwr.mm6933a2","volume":"69","author":"BH Lambdin","year":"2020","unstructured":"Lambdin BH. Overdose education and naloxone distribution within syringe service programs\u2014United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(33):1117\u201321.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"522_CR32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/03007995.2017.1334637","volume":"34","author":"GK Avetian","year":"2018","unstructured":"Avetian GK, et al. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations. Curr Med Res Opin. 2018;34:573\u20136.","journal-title":"Curr Med Res Opin"},{"key":"522_CR33","unstructured":"Overdose Deaths Accelerating During COVID-19. Centers for disease control and prevention. 2020. https:\/\/www.cdc.gov\/media\/releases\/2020\/p1218-overdose-deaths-covid-19.html."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00522-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T07:09:36Z","timestamp":1627024176000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00522-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00522-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-151919\/v1","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"19 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all study participants prior to enrollment. This study qualified as exempt from continuing review by the IRB of the University of Pennsylvania (IRB protocol #834304) and was registered on ClinicalTrials.gov (NCT04530591).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}